Synthesis of a new class of 2-anilino substituted nicotinyl arylsulfonylhydrazides as potential anticancer and antibacterial agents

Bioorganic and Medicinal Chemistry

Volumn 15, Issue 2, 2007, Pages 1004-1013

  Kamal, Ahmed ^a   Khan, M Naseer A ^a   Srinivasa Reddy, K ^a   Rohini, K ^a  

^a INDIAN INSTITUTE OF CHEMICAL TECHNOLOGY   (India)

Author keywords

2 Anilino substituted nicotinyl arylsulfonylhydrazides; Antibacterial agents; Anticancer agents

Indexed keywords

ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; HYDRAZIDE DERIVATIVE; N 1 4 [[2 [2 (4 CHLOROANILINO) 3 PYRIDYL]CARBONYLHYDRAZINO]SULFONYL] PHENYL ACETAMIDE; N 1 4 [[2 [2 (4 FLUOROANILINO) 3 PYRIDYL]CARBONYLHYDRAZINO]SULFONYL] PHENYL ACETAMIDE; N' 1 [2 (2,4 DICHLOROANILINO) 3 PYRIDYL]CARBONYL 4 FLUORO 1 BENZENESULFONOHYDRAZIDE; N' 1 [2 (4 CHLOROANILINO) 3 PYRIDYL]CARBONYL 2,4 DICHLORO 1 BENZENESULFONOHYDRAZIDE; N' 1 [2 (4 CHLOROANILINO) 3 PYRIDYL]CARBONYL 4 METHYL 1 BENZENESULFONOHYDRAZIDE; N' 1 [2 (4 FLUOROANILINO) 3 PYRIDYL]CARBONYL 4 CHLORO 1 BENZENESULFONOHYDRAZIDE; N' 1 [2 (4 FLUOROANILINO) 3 PYRIDYL]CARBONYL 4 FLUORO 1 BENZENESULFONOHYDRAZIDE; N' 1 [2 (4 METHOXYANILINO) 3 PYRIDYL]CARBONYL 4 METHYL 1 BENZENESULFONOHYDRAZIDE; N' 1 [[2 ANILINO 3 PYRIDYL]CARBONYL] 1 BENZENESULFONOHYDRAZIDE; SULFADIAZINE; SULFANILAMIDE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER INHIBITION; COLON CANCER; CONTROLLED STUDY; DRUG SCREENING; DRUG SYNTHESIS; FEMALE; GRAM NEGATIVE BACTERIUM; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY CANCER; LEUKEMIA; LUNG CANCER; MALE; MELANOMA; NONHUMAN; SUBSTITUTION REACTION;

ANILINE COMPOUNDS; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; BACTERIA; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; HYDRAZINES; INDICATORS AND REAGENTS; MAGNETIC RESONANCE SPECTROSCOPY; MICROBIAL SENSITIVITY TESTS; SPECTROMETRY, MASS, FAST ATOM BOMBARDMENT;

NEGIBACTERIA; POSIBACTERIA;

EID: 33845303215     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2006.10.027     Document Type: Article

References (32)

1. Buolamwini J.K. Curr. Opin. Chem. Biol. 3 (1999) 500
2. Jones D.A., and Fitzpatrick F.A. Curr. Opin. Chem. Biol. 3 (1999) 71
3. Drew J. Science 287 (2000) 1960
4. Supuran C.T., Casini A., Scozzafava A., and Mastrolorenzo A. Curr. Cancer Drug Targets 2 (2002) 55
5. Owa T., and Nagasu T. Exp. Opin. Ther. Patents 10 (2000) 1725
6. Supuran C.T., and Scozzafava A. Exp. Opin. Ther. Patents 10 (2000) 575
7. Supuran C.T., and Scozzafava A. Curr. Med. Chem.-Immunol., Endocrinol. Metab. Agents 1 (2001) 61
8. Lobb K.L., Hipskind P.A., Aikins J.A., Alvarez E., Cheung Y., Considine E.L., De Dios A., Durst G.L., Ferritto R., Grossman C.S., Giera D.D., Hollister B.A., Huang Z., Iversen P.W., Law K.L., Tiechao L.i., Ho-Shen Lin Lopez B., Lopez J.E., Cabrejas L.M.M., Denis J McCann D.J., Molero V., Reilly J.E., Richett M.E., Shih C., Teicher B., Wikel J.H., White W.T., and Mader M.M. J. Med. Chem 47 (2004) 5367
9. Medina J.C., Roche D., Shan B., Learned R.M., Frankmoelle W.P., Clark D.L., Rosen T., and Jaen J.C. Bioorg. Med. Chem. Lett. 9 (1999) 1843
10. Maren T.H. Annu. Rev. Pharmacol. Toxicol. 16 (1976) 309
11. Boyd A.E. Diabetes 37 (1988) 847
12. Koyanagi N., Nagasu T., Fujita F., Watanabe T., Tsukahara K., Funahashi Y., Fujita M., Taguchi T., Yoshino H., and Kitoh K. Cancer Res. 54 (1994) 1702
13. Yokoi A., Kuromitsu J., Kawai T., Nagasu T., Sugi N.H., Yoshimatsu K., Yoshino H., and Owa T. Mol. Cancer Ther. 1 (2002) 275
14. Yoshimatsu K., Yamaguchi A., Yoshino H., Koyanagi N., and Kitoh K. Cancer Res. 57 (1997) 3208
15. Nakatsu N., Yoshida Y., Yamazaki K., Nakamura T., Dan S., Fukui Y., and Yamori T. Mol. Cancer Ther. 4 (2005) 399
16. Mokotoff M., Brynes S., and Burckart G.J. J. Med. Chem. 21 (1978) 45
17. Supuran C.T., Winum J.Y., Dogne J.M., Casini A., de Leval X., Montero J.L., Scozzafava A., Vullo D., and Innocenti A. J. Med. Chem. 48 (2005) 2121
18. Ariesan V., Marie Mrs., Cuparencu B., and Safta L. Therapie 27 (1972) 309 (Fr)
19. Jouhari R., and Quinn P. Heterocycles 38 (1994) 2243
20. Fand T.I., and Spoerri P.E. J. Am. Chem. Soc. 74 (1952) 1345
21. Huntress E.H., and Carten F.H. J. Am. Chem. Soc. 62 (1940) 511
22. Halperin J.A., Natarajan A., Guo Y., Harbinski F., Fan Y.H., Chen H., Luus L., Diercks J., Aktas H., and Chorev M. J. Med. Chem. 47 (2004) 4979
23. Alley M.C., Scudiero D.A., Monks A., Hursey M.L., Czerwinski M.J., Fine D.L., Abbot B.J., Mayo J.G., Shoemaker R.H., and Boyd M.R. Cancer Res. 48 (1988) 589
24. Grever M.R., Schepartz S.A., and Chabner B.A. Semin. Oncol. 19 (1992) 622
25. Boyd M.R., and Paull K.D. Drug Dev. Res. 34 (1995) 91
26. Monks A., Scudiero D., Skehan P., Shoemaker R., Paull K., Vistica D., Hose C., Langley J., Cronise P., Vaigro-Wolff A., Gray-Goodrich M., Campbell H., Mayo J., and Boyd M. J. Natl. Cancer Inst. 83 (1991) 757
27. Weinstein J.N., Myers T.G., Connor P.M., Friend S.H., Fornace Jr. A.J., Kohn K.W., Fojo T., Bates S.E., Rubinstein L.V., Anderson N.L., Buolamwini J.K., van Osdol W.W., Monks A.P., Scudiero D.A., Sausville E.A., Zaharevitz D.W., Bunow B., Viswanadhan V.N., Johnson G.S., Wittes R.E., and Paull K.D. Science 275 (1997) 343
28. Data concerning the NCI screening methods in detail are accessible from the NCI via the Internet from the following address: http://dtp.nci.nih.gov/branches/btb/ivclsp.html.
29. Yoshino H., Ueda N., Niijima J., Sugumi H., Kotake Y., Yoshimatsu K., Asada M., Watanabe T., Nagasu T., Tsukahara K., Iijima A., and Kitoh K. J. Med. Chem. 35 (1992) 2496
30. ALOGPS 2.1 software available at http://www.vcclab.org/lab/alogps.
31. Tetko I.V., and Tanchuk V.Y.J. Chem. Inf. Comput. Sci. 42 (2002) 1136
32. Prescott L.M., Harley J.P., and Klein D.A. Microbiology. 5th ed. (2002), McGraw-Hill, New York Chapter 35, pp 805-825